Impact BioMedical, Inc. (IBO)vsEli Lilly and Company (LLY)
IBO
Impact BioMedical, Inc.
$0.66
-2.59%
HEALTHCARE · Cap: $71.16M
LLY
Eli Lilly and Company
$934.60
+3.07%
HEALTHCARE · Cap: $760.43B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 203684278% more annual revenue ($65.18B vs $32,000). LLY leads profitability with a 31.7% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 78/100 (B+).
IBO
Avoid15
out of 100
Grade: F
LLY
Strong Buy78
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.5x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : IBO
The strongest argument for IBO centers on Debt/Equity.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bear Case : IBO
The primary concerns for IBO are Revenue Growth, EPS Growth, Market Cap.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Key Dynamics to Monitor
IBO profiles as a value stock while LLY is a growth play — different risk/reward profiles.
LLY is growing revenue faster at 42.6% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (78/100 vs 15/100), backed by strong 31.7% margins and 42.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Impact BioMedical, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Impact BioMedical, Inc. is a forward-thinking biotechnology firm dedicated to the development of pioneering therapeutics and technologies that tackle pressing healthcare issues. The company employs cutting-edge research and development methodologies to enhance patient health outcomes and elevate quality of life. With a strong intellectual property portfolio and a focus on scientific excellence, Impact BioMedical is strategically positioned for significant growth in the dynamic healthcare landscape. Its diverse product pipeline and strategic partnerships present promising opportunities for institutional investors seeking to invest in the transformative advancements of the biopharmaceutical sector.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?